Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

not_yet_recruiting240%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

NCT07327788
recruitingphase_1

PULSAR Combined With Immunotherapy and Chemotherapy

NCT07291947
recruitingphase_2

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

NCT07289997
not_yet_recruitingphase_2

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

NCT07131501
not_yet_recruitingphase_2

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

NCT07128251

Clinical Trials (5)

Showing 5 of 5 trials
NCT07327788Phase 2

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

Recruiting
NCT07291947Phase 1

PULSAR Combined With Immunotherapy and Chemotherapy

Recruiting
NCT07289997Phase 2

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Recruiting
NCT07131501Phase 2

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Not Yet Recruiting
NCT07128251Phase 2

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5